Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight (GZBF)
비만 또는 과체중으로 체중 관련 합병증을 가진 참가자를 대상으로 위약과 비교한 주 1회 LY3437943의 2상 연구
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
After screening (up to 6 weeks), eligible participants are randomized to one of several dose-escalation regimens leading to maintenance doses of 1, 4, 8, or 12 mg retatrutide (or placebo) administered once weekly for 48 weeks, followed by a 4-week safety follow-up. Two maintenance dose levels (4 mg and 8 mg) include alternative escalation schedules to evaluate tolerability. The primary efficacy evaluation is at Week 24 (percent change in body weight), with additional weight, anthropometric, and safety assessments through Week 48.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Seni S Lu, Phd
- 전화번호: +86 13076790030
- 이메일: Seni-Lu@beijing-biotech.com
연구 장소
-
-
Guangdong
-
Shenzhen, Guangdong, 중국, 518036
- 모병
- Peking University Shenzhen Hospital
-
연락하다:
- Zhen J Peng, Phd
- 전화번호: +8613076790039
- 이메일: Zhen-Peng@beijing-biotech.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 to 75 years (inclusive) at time of informed consent.
- BMI ≥30 and ≤50 kg/m², OR BMI ≥27 and <30 kg/m² with at least 1 weight-related comorbidity (hypertension; dyslipidemia; or cardiovascular disease such as ischemic CVD or NYHA Class I-II heart failure).
- Motivated and able/willing to self-inject (or have trained assistance if needed) and follow study procedures, including lifestyle advice and questionnaires.
- Subgroup (NAFLD addendum): liver fat content ≥10% by MRI-PDFF (for participants invited to the addendum).
- Male and/or female; contraception requirements apply; women of childbearing potential must have negative pregnancy tests at specified visits and should not be breastfeeding.
- Capable of giving signed informed consent and complying with protocol requirements.
Exclusion Criteria:
- History of diabetes mellitus (type 1 or type 2), ketoacidosis, or hyperosmolar state/coma.
- Screening lab values suggestive of diabetes (HbA1c ≥6.5%; fasting glucose ≥126 mg/dL; or random glucose ≥200 mg/dL).
- Self-reported change in body weight >5 kg within 3 months prior to screening.
- Prior or planned surgical treatment for obesity (exceptions: liposuction/abdominoplasty >1 year prior).
- Current/planned endoscopic or device-based obesity therapy, or device removal within last 6 months (e.g., intragastric balloon, gastric artery embolization).
- Renal impairment: eGFR <45 mL/min/1.73 m² (CKD-EPI) at screening.
- Clinically significant gastric emptying abnormality (e.g., severe gastroparesis) or chronic drugs affecting GI motility.
- History of acute or chronic pancreatitis (exception for resolved gallstone pancreatitis post-cholecystectomy).
- TSH outside 0.4 to 6.0 mIU/L at screening (with protocol-defined exceptions).
- Obesity due to other endocrine disorders (e.g., Cushing's) or monogenic/syndromic obesity (e.g., Prader-Willi).
- Psychiatric exclusion criteria including unstable major depressive disorder/severe psychiatric disorder within 2 years; lifetime suicide attempt; PHQ-9 score ≥15; or specified Columbia-Suicide Severity Rating Scale (C-SSRS) findings within past month.
- Uncontrolled hypertension (systolic ≥160 mmHg and/or diastolic ≥100 mmHg) or elevated resting pulse rate (>100 bpm) at baseline.
- Recent (within 3 months) major cardiovascular events (e.g., MI, stroke, unstable angina, CHF hospitalization); tachyarrhythmia syndromes; NYHA Class III-IV CHF; or ECG abnormalities interfering with interpretation.
- Acute/chronic hepatitis or liver disease other than NAFLD; or screening labs: ALT >3× ULN, ALP >1.5× ULN, or total bilirubin >1.5× ULN (with exception).
- Elevated calcitonin at Visit 1 per protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2.
- Active/untreated malignancy or remission <5 years (with protocol exceptions for certain in-situ/skin cancers).
- Contraindication to GLP-1 receptor agonists, or other conditions that could prevent protocol compliance (including drug/alcohol abuse or eating disorder), per investigator judgment.
- Alcohol consumption >14 units/week (women) or >21 units/week (men).
- Recent marijuana/THC-containing product use within 3 months or unwillingness to abstain during trial (protocol exception for cannabidiol oil if agrees to refrain).
- Organ transplant history (except corneal transplant) or awaiting transplant.
- Hematologic conditions interfering with HbA1c measurement; recent large blood donation/transfusion/severe blood loss; hemoglobin below protocol thresholds.
- Severe atopy/multiple severe allergies or severe hypersensitivity reactions.
- Fasting triglycerides >500 mg/dL at screening (with stability requirement for lipid-lowering therapy).
- Significant active, uncontrolled medical condition or history posing risk or interfering with data interpretation, per investigator judgment.
- History of symptomatic gallbladder disease within past 2 years (protocol-defined exceptions after cholecystectomy).
- History of documented HIV infection.
- Chronic systemic glucocorticoid therapy within 3 months or active autoimmune abnormality likely to require systemic steroids during study (with specified formulation exceptions).
- Recent medications that may cause significant weight gain (e.g., tricyclic antidepressants, atypical antipsychotics, mood stabilizers) within 3 months.
- Recent use (within 3 months) of medications or remedies intended to promote weight loss (examples listed in protocol, including GLP-1 RAs).
- Use of metformin or other glucose-lowering medications (e.g., for PCOS or diabetes prevention) not permitted at entry.
- Started implantable/injectable contraceptives within 18 months prior to screening (IUDs allowed if used ≥3 months).
- Known allergies to GLP-1 receptor agonists or LY3437943.
- Currently enrolled in another investigational study or recent participation/treatment within 30 days (or 5 half-lives, whichever longer).
- Previously received LY3437943 in this or another study.
- Investigator site personnel directly affiliated with the study and/or their immediate family; or Lilly employees.
- Note: The publicly posted protocol references additional exclusion criteria numbered 52-57 in a separate protocol addendum (not included in the posted protocol PDF).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 레타트루티드(LY3437943) 1mg 주 1회(용량 증가 없음)
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: 레타트루티드 4 mg 주 1회, 증량 하위군 (a): 2 mg → 4 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: 레타트루타이드 4 mg 주 1회, 하위 그룹 (b): 4 mg 시작 (증량 없음).
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: Retatrutide 8 mg 주 1회, 하위군 (a): 2 mg → 4 mg → 8 mg
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: Retatrutide 12 mg 주 1회 투여: 2 mg → 4 mg → 8 mg → 12 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: 주 1회 위약 투여 (눈가림을 유지하기 위해 일치하는 증량 일정 적용).
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
|
실험적: Retatrutide 8 mg 주 1회, 하위 그룹 (b): 4 mg → 8 mg.
|
subcutaneous injection, once weekly (dose per assigned arm). subcutaneous injection, once weekly (schedule matched to an active arm). Standardized diet and physical activity counseling throughout the study. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
무작위 배정/기준선부터 24주까지의 체중 평균 백분율 변화.
기간: 24주
|
24주
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
기저선에서 48주까지의 체중 변화 평균 백분율
기간: 48주
|
48주
|
|
참가자의 24주 및 48주 시점에서 체중 감소율이 5% 이상, 10% 이상, 15% 이상 달성된 비율
기간: 48주
|
48주
|
|
24주 및 48주 시점 체중(kg)의 평균 변화.
기간: 48주
|
48주
|
|
24주 및 48주 시점의 BMI(kg/m²) 평균 변화
기간: 48주
|
48주
|
|
24주 및 48주 시점의 허리둘레(cm) 평균 변화
기간: 48주
|
48주
|
|
안전성 및 내약성 결과 (예: 치료 중 발생한 이상반응; 중대한 이상반응; 이상반응으로 인한 치료 중단).
기간: 48주
|
48주
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- J1I-MC-GZBS
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .